[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-390501-105":59,"doc-detail-390501-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","guidelines-version-120-october-2023","GUIDELINES - Version 12.0 - October 2023","","EACS Guidelines Version 12.0 (October 2023) provide structured recommendations for managing HIV across initial and subsequent visits, including assessment, readiness to start and maintain ART, initiation strategies for ART-naïve adults, switch options for virologically suppressed patients, and approaches for virological failure. The guideline also addresses key clinical scenarios such as primary HIV infection, pregnancy, TB/HIV co-infection, and prophylaxis options (PEP/PrEP). It further covers drug-drug interactions, co-morbidities, and prevention and management of cardiovascular, metabolic, bone, liver, kidney, mental health, and other associated conditions.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/guidelines-version-120-october-2023/390501/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/guidelines-version-120-october-2023/390501.png","ImageObject",300,407,{"name":92,"@type":93},"Sarah ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-25",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What does EACS Guidelines Version 12.0 cover for HIV care across visits?","Question",{"text":113,"@type":114},"It provides recommendations for assessment of initial and subsequent visits, including readiness to start and maintain ART, initiation in ART-naïve adults, and management approaches for virological suppression or failure.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How are ART-related special situations addressed in the guideline?",{"text":118,"@type":114},"The guideline includes specific sections for primary HIV infection, pregnancy with HIV (or considering pregnancy), TB/HIV co-infection, and prophylaxis strategies such as PEP and PrEP.",{"name":120,"@type":111,"acceptedAnswer":121},"What areas are included under drug-drug interactions and prescribing issues?",{"text":122,"@type":114},"It covers interactions between ARVs and non-ARV drugs across multiple categories (e.g., analgesics, anticoagulants/antiplatelet agents, antidepressants, antihypertensives, anti-infectives, anti-malarials, and anti-tuberculosis drugs), plus relevant administration and dose adjustment topics.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},390501,1790652355,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","GUIDELINES  \nVersion 12.0 October 2023  \nEnglish  \nTable of Contents  \n\n| Introduction to EACS Guidelines 2023 | 3 |\n| --- | --- |\n| Summary of Changes from v11 .1 to v 12.0 | 4 |\n| Panel Members | 5 |\n| Governing Board Members | 5 |\n| Abbreviations | 6 |\n\nPart I  \n\n| Assessment of Initial & Subsequent Visits 7 |  |\n| --- | --- |\n| Part II |  |\n| ART | 10 |\n| Assessing Readiness to Start and Maintain ART | 10 |\n| Recommendations for Initiation of ART in Persons with Chronic Infection without Prior ART Exposure | 12 |\n| Initial Combination Regimen for ART-naive Adults | 13 |\n| Primary HIV Infection (PHI) | 15 |\n| Switch Strategies for Virologically Suppressed Persons | 16 |\n| Virological Failure | 17 |\n| Treatment of Pregnant Women Living with HIV or Women Considering Pregnancy | 18 |\n| ART in TB/HIV Co-infection | 20 |\n| Post-exposure Prophylaxis (PEP) | 22 |\n| Pre-exposure Prophylaxis (PrEP) | 23 |\n| Adverse Effects ofARVs and Drug Classes | 24 |\n| Part III |  |\n| Drug-drug Interactions and Other Prescribing Issues | 26 |\n| Drug-drug Interactions between ARVs and Non-ARVs | 28 |\n| Drug-drug Interactions between Analgesics and ARVs | 30 |\n| Drug-drug Interactions between Anticoagulants/Antiplatelet Agents andARVs | 31 |\n| Drug-drug Interactions between Antidepressants and ARVs | 32 |\n| Drug-drug Interactions between Antihypertensives and ARVs | 33 |\n| Drug-drug Interactions between Anti-infective Drugs for OIs and STIs andARVs | 35 |\n| Drug-drug Interactions between Anti-malarial Drugs and ARVs | 37 |\n| Drug-drug Interactions between Anti-tuberculosis Drugs and ARVs | 38 |\n| Drug-drug Interactions between Anxiolytics and ARVs | 40 |\n| Drug-drug Interactions between Bronchodilators (for COPD) and ARVs | 41 |\n| Drug-drug Interactions between Contraceptives and ARVs | 42 |\n| Drug-drug Interactions between Corticosteroids and ARVs | 44 |\n| Drug-drug Interactions between COVID-19 Therapies andARVs | 45 |\n| Drug-drug Interactions between Hormone Replacement Therapy (HRT) andARVs | 46 |\n| Drug-drug Interactions between Immunosuppressants (for SOT) andARVs | 47 |\n| Drug-drug Interactions between Pulmonary AntihypertensivesandARVs | 48 |\n| Drug-drug interactions between Viral Hepatitis Drugs and ARVs | 49 |\n| Administration ofARVs in persons with Swallowing Difficulties | 50 |\n| Dose Adjustment ofARVs for Impaired Hepatic Function | 53 |\n| Dose Adjustment ofARVs for Impaired Renal Function | 54 |\n| Selected Non-ARV Drugs Requiring Dosage Adjustment in Renal Insufficiency | 56 |\n| Prescribing in Older Persons with HIV | 58 |\n| Drug Classes to Avoid in Older Persons with HIV | 59 |\n| Drug Classes to Deprescribe in Older Persons with HIV in Presence of Certain Conditions | 60 |\n| Dosage Recommendations for Hormone Therapy when Used at High Doses for Gender Transitioning | 61 |\n\n\n| Part IV |  |\n| --- | --- |\n| Prevention and Management of Co-morbidities | 62 |\n| Substance Use: Alcohol | 63 |\n| Opioid Addiction, Pharmacological Treatment | 64 |\n| Cancer: Screening Methods | 65 |\n| Cancer: Treatment Monitoring | 66 |\n| Lifestyle Interventions | 67 |\n| Prevention of Cardiovascular Disease (CVD) | 68 |\n| Hypertension: Diagnosis, Grading and Management | 69 |\n| Hypertension: Drug Sequencing Management | 70 |\n| Drug-drug Interactions between Antihypertensives and ARVs | 71 |\n| Type 2 Diabetes: Diagnosis | 73 |\n| Type 2 Diabetes: Management | 74 |\n| Dyslipidaemia | 76 |\n| Treatment Goals for LDL-c to reduce Cardiovascular Risk Depending on CV Risk Estimation | 77 |\n| Bone Disease: Screening and Diagnosis | 78 |\n| Vitamin D Deficiency: Diagnosis and Management | 79 |\n| Approach to Fracture Reduction | 80 |\n| Kidney Disease: Definition, Diagnosis and Management | 81 |\n| ARV-associated Nephrotoxicity | 82 |\n| Indications and Tests for Proximal Renal Tubulopathy (PRT) | 83 |\n| Dose Adjustment ofARVs for Impaired Renal Function | 84 |\n| Work-up and Management of Persons with Increased ALT/AST | 86 |\n| Liver Cirrhosis: Classification and Surveillance |","cbCaicQ4zLMduLQn","https://ap.wps.com/l/cbCaicQ4zLMduLQn","pdf",4316191,163,"English","# Introduction to EACS Guidelines 2023\n# Summary of Changes from v11.1 to v12.0\n# Panel Members\n# Governing Board Members\n# Abbreviations\n# Assessment of Initial & Subsequent Visits\n# ART\n## Assessing Readiness to Start and Maintain ART\n## Recommendations for Initiation of ART in Persons with Chronic Infection without Prior ART Exposure\n## Initial Combination Regimen for ART-naive Adults\n## Primary HIV Infection (PHI)\n## Switch Strategies for Virologically Suppressed Persons\n## Virological Failure\n## Treatment of Pregnant Women Living with HIV or Women Considering Pregnancy\n## ART in TB/HIV Co-infection\n## Post-exposure Prophylaxis (PEP)\n## Pre-exposure Prophylaxis (PrEP)\n# Drug-drug Interactions and Other Prescribing Issues\n## Drug-drug Interactions between ARVs and Non-ARVs\n## Drug-drug Interactions between Analgesics and ARVs\n## Drug-drug Interactions between Anticoagulants/Antiplatelet Agents and ARVs\n## Drug-drug Interactions between Antidepressants and ARVs\n## Drug-drug Interactions between Antihypertensives and ARVs\n## Drug-drug Interactions between Anti-infective Drugs for OIs and STIs and ARVs\n## Drug-drug Interactions between Anti-malarial Drugs and ARVs\n# Prevention and Management of Co-morbidities\n## Substance Use: Alcohol\n## Opioid Addiction, Pharmacological Treatment\n## Cancer: Screening Methods\n## Cancer: Treatment Monitoring\n## Lifestyle Interventions\n## Prevention of Cardiovascular Disease (CVD)","[{\"question\":\"What does EACS Guidelines Version 12.0 cover for HIV care across visits?\",\"answer\":\"It provides recommendations for assessment of initial and subsequent visits, including readiness to start and maintain ART, initiation in ART-naïve adults, and management approaches for virological suppression or failure.\"},{\"question\":\"How are ART-related special situations addressed in the guideline?\",\"answer\":\"The guideline includes specific sections for primary HIV infection, pregnancy with HIV (or considering pregnancy), TB/HIV co-infection, and prophylaxis strategies such as PEP and PrEP.\"},{\"question\":\"What areas are included under drug-drug interactions and prescribing issues?\",\"answer\":\"It covers interactions between ARVs and non-ARV drugs across multiple categories (e.g., analgesics, anticoagulants/antiplatelet agents, antidepressants, antihypertensives, anti-infectives, anti-malarials, and anti-tuberculosis drugs), plus relevant administration and dose adjustment topics.\"}]","GUIDELINES - Version 12.0 - October 2023 | PDF",1790335282,411]